Intercept Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Intercept Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Intercept Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Intercept Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a clinical-stage specialty pharmaceutical company with a focus on chronic liver diseases. Its focused research and development (R&D) activities, strong market position in liver disease therapeutics and pipeline of innovative products are its major strengths, even as private ownership is a cause for concern. Product pipeline, innovative use of FXR agonism, and market potential for alcoholic hepatitis could provide growth opportunities for the company. However, competitive pressure, dependence on third-party manufacturers and compliance with regulatory requirements could hamper the company's results of operations.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer